Alimera Sciences (ALIM) Stock Price, News & Analysis

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALIM shares.
View ALIM analyst ratings or view top-rated stocks.

3 brokers have issued 1-year price targets for Alimera Sciences' shares. Their ALIM share price targets range from $5.00 to $10.00. On average, they anticipate the company's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 124.6% from the stock's current price.
View analysts price targets for ALIM or view top-rated stocks among Wall Street analysts.

Alimera Sciences' stock was trading at $4.32 at the beginning of the year. Since then, ALIM stock has decreased by 22.7% and is now trading at $3.34.
View the best growth stocks for 2024 here.

Alimera Sciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 108,800 shares, an increase of 26.8% from the March 15th total of 85,800 shares. Based on an average daily volume of 81,900 shares, the short-interest ratio is presently 1.3 days.
View Alimera Sciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ALIM earnings forecast.

Alimera Sciences, Inc. (NASDAQ:ALIM) released its quarterly earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by $0.09. The biopharmaceutical company earned $26.31 million during the quarter, compared to analyst estimates of $25.10 million. Alimera Sciences had a negative net margin of 24.93% and a negative trailing twelve-month return on equity of 130.90%. During the same quarter in the prior year, the business posted ($0.54) earnings per share.

Alimera Sciences's stock reverse split on the morning of Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Alimera Sciences updated its FY 2024 earnings guidance on Thursday, March, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $105.0 million-, compared to the consensus revenue estimate of $103.7 million.

2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).

Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.